Request access to Pritelivir for immunocompromised patients with refractory HSV infections
AiCuris collaborates with myTomorrows to support expanded access to Pritelivir.
This site is intended for licensed healthcare professionals only. If you are a patient or caregiver, please speak with your treating physician about potential access to treatment.
Submit a request
Important information before you begin
In collaboration with myTomorrows, AiCuris provides a potential pathway to access Pritelivir oral tablets for the treatment of active Herpes Simplex Virus (HSV) mucocutaneous infections that are refractory, with or without resistance, to both acyclovir and foscarnet, in immunocompromised patients.
This request form is exclusively intended for use by healthcare professionals.
Each request is reviewed individually, based on the patient’s clinical situation and the program’s eligibility criteria. A detailed medical rationale may be required to assess eligibility.
Do not include any personally identifiable patient information in your submission.
Healthcare provider information
Please provide your full name, contact details, country of practice, and the name of your institution.
Patient information
Confirm the product of interest, review the patient eligibility criteria, and share the rationale for your request. Please ensure no personally identifiable patient information is included.
Submit request
Once all required fields are completed, submit the form for review. After review you will receive a confirmation of your request.
Evaluation of request
Your request will be reviewed by our team within 1 business day. We’ll follow up by phone or email if additional details are required and to confirm next steps.